Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug

BLA Filing Planned For Q2 2026

 
• By Mandy Jackson
  
Dyne's DMD drug performed better than placebo across six functional measures (Shutterstock)

More from Clinical Trials

More from R&D